All filters
Slidesets
O_04 - Blood-based Protein Biomarkers of NASH | Dr. S. Williams
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_05 - Validation of multiparametric MRI in the assessment and staging of non-alcoholic fatty liver disease | Dr. P. Eddowes
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
LiverMultiScan – quantitative MR imaging for NASH | Rajarshi Banerjee
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_06 - Longitudinal changes in FIB-4 and improvement in fibrosis stage with obeticholic acid: A secondary analysis of FLINT Trial | Dr. A. Sanyal
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Need for Biomarker Development in Non-Alcoholic Fatty Liver Disease | Eric Lefebvre, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Principles of Biomarker Development | Margery Connelly, PhD, MBA
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Quantitative measures of liver health | Grey Everson, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Defining the gold standard in Biomarker Validation in NAFLD | Arun Sanyal, MD, MBBS
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_02 - Performance of non-invasive tests in the staging of fibrosis in patients with NAFLD: interim results of a prospective multicentre study | Dr. P. Eddowes
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Biomarkers: what can be learned from type 2 diabetes | Manu Chakravarthy, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Proteomics-based biomarker discovery in NAFLD | Naga Chalasani, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Study Design and endpoints in Omics-based biomarker studies | Stephen Williams, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Lipid and Bile acids as NAFLD-related biomarkers | Puneet Puri, MBBS, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Potential approach to identify the NAFLD patient who will develop HCC | Yujin Hoshida, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Simple laboratory based indices | Ray Kim, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Biomarker development in pediatric NAFLD: special challenges in a special population | Saul Karpen, MD, PhD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Dynamic measurement of physiologic functions: any role in NASH diagnostics | Stephen Previs, MD
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Microbiome: diagnostic considerations | Patrick Gillevet
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
O_03 - A non-invasive lipidomic test accurately discriminates NASH from steatosis: a blind validation study | Dr. T. Montgomery
Presented at:
International Workshop on NASH Biomarkers 2016
Slidesets
Management of DAA Failures - Gregory T. Everson, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Who Should We Treat? What is the “Point-of-No-Return”? - Norah Terrault, MD, MPH, FAASLD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Treatment Experienced GT3 patient with Cirrhosis - Geoffrey McCaughan, MD, PhD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016
Slidesets
Is Treatment Cost-effective? - Kosh Agarwal, MD
Presented at:
Optimize Workshop: Using DAAs in Patients with Cirrhosis and Liver Recipients 2016